{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Faridar A"],"funding":["Alzheimer&apos;s Association","Alzheimer's Association"],"pagination":["54"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10652426"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.<h4>Clinicaltrials</h4>gov/ct2/show/NCT05821153."],"journal":["Translational neurodegeneration"],"pubmed_title":["A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease."],"pmcid":["PMC10652426"],"funding_grant_id":["PTCG-21-1818034"],"pubmed_authors":["Roman GC","Thome AD","Pascual MB","Grundman M","Zhao W","Appel SH","Davis CS","Masdeu JC","Beers DR","Nakawah MO","Faridar A","Eid AM"],"additional_accession":[]},"is_claimable":false,"name":"A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.","description":"<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.<h4>Clinicaltrials</h4>gov/ct2/show/NCT05821153.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-07-14T19:25:28.549Z","creation":"2024-10-19T11:20:59.921Z"},"accession":"S-EPMC10652426","cross_references":{"pubmed":["37968718"],"doi":["10.1186/s40035-023-00387-5"]}}